^
    Back
    Association details:
    Biomarker:HRAS G12D
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:erlotinib (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Head Neck
    Title:

    HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

    Excerpt:
    All 7 cell lines were wild-type for EGFR and KRAS regardless of erlotinib sensitivity; however, 1 erlotinib-resistant cell line (HN31) harbored an HRAS G12D mutation.
    DOI:
    10.1002/hed.23499